National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Insulin degludec/liraglutide (IDegLira) (Xultophy®)

IDegLira is indicated for the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control.

Rapid Review

Commenced Completed Outcome
19/09/2016 17/10/2016 Full Pharmacoeconomic Evaluation Recommended at the Submitted Price.



The HSE has approved reimbursement; July 2019.